Impact BioMedical (IBO): Market Cap to Revenue

Symbol and logo of brand impactbiomedinc.com (IBO)

Impact BioMedical Inc (IBO) is developing a biomedical holding company based on the implementation of the 3F repellent and the sale of patents. Unique plant-based formulas that block viruses provide moderate pricing power. P/S levels on the chart demonstrate the market valuation of revenue, where the 1016.10 indicator determines this level. The company's strategy is based on licensing intellectual property to bypass direct price competition.

Impact BioMedical Inc (IBO) - P/S Multiple from 09/17/2024 to 11/13/2026

Impact BioMedical Inc (IBO) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Chart Impact BioMedical, Inc.|IBO - Price Target Chart
- stock exchange capitalization data:
Market Valuation Impact BioMedical|IBO - Total Company Value
- book value of equity indicators:
Share Book Value Impact BioMedical|IBO - Book Capitalization|Market Capitalization to Book Value Ratio impactbiomedinc.com|IBO - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Impact BioMedical Inc|IBO - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio impactbiomedinc.com|IBO - Company Total Debt|Debt to Net Assets Ratio Impact BioMedical|IBO - Company Long-Term Debts|Company Short-Term Debt Impact BioMedical|Interim Coverage Ratio impactbiomedinc.com
- earnings and valuation multiples indicators:
IBO - Company Net Income|Expected Net Profit Impact BioMedical Inc|IBO - Price to Earnings Ratio|Projected Price to Earnings Impact BioMedical, Inc.|IBO - PEG Multiple|Company Value to EBITDA Impact BioMedical|IBO - Operating profit EBITDA|Earnings per share for the last 12 months Impact BioMedical|IBO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months impactbiomedinc.com|IBO - Earnings growth in current year|Expected earnings per share growth for next year Impact BioMedical Inc
- issuer revenue and sales details:
IBO - Revenue and Sales Volume|Projected Sales Volume impactbiomedinc.com|IBO - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Impact BioMedical
Summary company analytics:Impact BioMedical, Inc., IBO
Original product of Impact BioMedical, Inc.

Impact BioMedical Inc (IBO) is developing high-tech R&D capabilities in biomedicine and antiviral solutions, making revenue the key basis for assessing its scalability. The relationship between market capitalization and sales volume, represented by the price-to-sales ratio, reveals deviations of market value from the average, signaling asset overvaluation when the metric exceeds standard deviation boundaries and a probable reversion to the median.

Competing companies

Price-to-Revenue Coefficient haleon.com|Price-to-Revenue Ratio Kenvue KVUE|VRNA - Market Cap to Revenue|MENS - Price-to-Revenue Ratio|Price-to-Sales Ratio LGND|AMRX: P/S Multiple|perrigo.com (PRGO) - P/S Multiple|ALVO (Alvotech SA) - P/S Multiple|Market Cap to Revenue Liquidia Corp (LQDA)|Market Cap to Revenue GLPG (Galapagos Genomics)|Market Cap to Sales Volume ANIP|MannKind Corporation - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio AMPH|Pacira BioSciences, Inc. - P/S Multiple|SPRY: Price-to-Revenue Ratio|TBPH: P/S Multiple|AQST - Price-to-Revenue Coefficient|Price-to-Revenue Ratio scPharmaceuticals, Inc.|Price to Sales Tectonic TECX|Price-to-Revenue Ratio Tonix Pharmaceuticals Holding Corp. (TNXP)|Market Cap to Revenue sxtchina.com SXTC|P/S Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|BioHarvest Sciences Inc (BHST) - Price to Sales|eXoZymes Inc - P/S Multiple|ORMP (Oramed Pharmaceuticals) - Market Cap to Revenue Ratio|ENTX: P/S Multiple|HYFT - Price-to-Revenue Coefficient|ABVC (ABVC BioPharma Inc) - P/S Multiple|Market Cap to Revenue Cumberland Corp (CPIX)|P/S Multiple QNTM|P/S Multiple fibrogen.com (FGEN)|Price-to-Revenue Ratio Telomir Pharmaceuticals, Inc. TELO|Rani Therapeutics Holdings - Price-to-Revenue Ratio|SNYR: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RLYB (Rallybio Corporation)|LEXX: P/S Multiple|PULM - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Pheton Holdings Limited|Market Cap to Revenue Ratio APM (Aptorum)|P/S Multiple LYRA|Market Cap to Revenue tnfpharma.com TNFA|P/S Multiple YCBD (cbdMD)|Price-to-Revenue Coefficient painreform.com (PRFX)|Auris Medical - P/S Multiple|LIPO: Price-to-Revenue Ratio|Optinose (OPTN) - Price-to-Revenue Ratio|Price to Sales Pieris Pharma (PIRS)|Price-to-Revenue Ratio Procaps Group S.A.|petrospharma.com - Price-to-Sales Ratio|P/S Multiple QLI|SLRN (Acelyrin Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple TFFP (TFF Pharma)